AltPep
Jae Hyun Park has over 18 years of experience in the pharmaceutical and biopharmaceutical industry. Jae Hyun began their career in 2003 as an Application/Peptide Chemist at Advanced ChemTech, Inc. In 2005, they moved to Gyros Protein Technologies AB as an Application Chemist. From 2008 to 2014, they worked at Purdue Pharma L.P. as a Principal Investigator and Senior Research Investigator. In 2014, they joined HealthTell as a Senior Scientist. From 2016 to 2021, they worked at Oragenics, Inc. as Senior Director of Drug Development and Director of Drug Development. In 2021, they were appointed as the Director of Drug Discovery Development at AltPep Corporation.
Jae Hyun Park began their educational journey in 1995 when they attended The University of Auckland, earning their Ph.D. in Organic Chemistry in 2003. In 2021, they began pursuing an Executive MBA at the University of Washington - Michael G. Foster School of Business, which they are expected to complete in 2023.
AltPep
AltPep Corporation is a biomedical startup with a breakthrough approach for diagnosing and treating some of the world’s most intractable diseases: amyloid diseases. They are currently focusing on CNS disorders, in particular Alzheimer’s Disease (AD). They target and seek to neutralize the early toxic oligomers behind these amyloid diseases, which in the case of AD are due to aggregation of the Amyloid-beta peptide (Abeta).